November 9, 2021 7:26am

Still watching the earnings releases

Earnings: Vericel (VCEL) and Applied Genetic Technologies (AGTC) on 11/9,

Pre-open indications: 4 SELLs, 3 BUYs and 1 Pump (or No Promote)

What I provide is an intelligence daily. RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Remember that overnight and pre-open actions in futures doesn't necessarily translate into actual trading in the coming day’s session.

Dow futures are DOWN -0.06% (-22 points), S&P futures are UP +0.04% (+2 points) and NASDAQ futures are UP +0.18% (+29 point)

 

U.S. stock futures were slightly lower during early pre-open trading on Tuesday, 11/9/21,

European stocks were subdued

Asia-Pacific stocks were mixed as Japan dropped Mainland Chinese stocks finished the trading day higher.

 

Economic data Docket: Investors are looking ahead to fresh inflation readings in the U.S. in the next few days with the latest producer price index due Tuesday and the consumer price index slated expected on Wednesday. <CNBC>

 

Henry’omics:

The major averages closed at records, boosted by strength in infrastructure stocks.

 

If you didn’t remember what happen at Monday night’s close and the quarter’s “number’s” impact, you won’t be prepared for today’s session:

Monday’s evening’s recap: “RegMed Investors’ (RMi) closing bell: the sector faded even as small-cap stocks led on the upside and held near their highs” … https://www.regmedinvestors.com/articles/12173

Q4: November, 3 positive and 3 negative close to date

  • October, 8 positive and 13 negative closes

 

Companies in my headlights – It’s your decision; I provide an idea and context:

SELL with a Pump or no promote:

Biostage (BSTG) closed up +$0.07 with 7,082 shares traded after being down -$0.60 after Friday’s flat again at $2.60 with 9,003 shares traded after Thursday’s flat with 82 shares traded, Wednesday’s -$0.40 to $2.60 with 1,208 shares traded, Tuesday’s -$0.10 to $3.00 with 200 shares traded following Monday’s flat again with 80 shares traded and the previous Friday’s flat with 95 shares traded.

  • What’s there to invest in – the “Sword of Damocles” hanging over its recent insurance company rejection of legal expense/costs of a terminal death suit against the company?
  • For a company with NO clinical trial, an a one (1) and a half year approved IND, four (4) employees and NO CRO <clinical research organization> initiation.

 

Probabilities versus aftermarket/pre-open share pricing indication moves:

SELL:

Chinook Therapeutics (KDNY) closed down -$1.77 with an aftermarket dive of -$0.81 or -5.71% after proposing a public offering Intending to offer and sell 6,000,000 shares.

Ionis Pharmaceuticals (IONS) closed up +$1.19 to $34.88 after Friday’s -$0.94 with a negative -$0.38 or -1.09% aftermarket indication.

BioLife Solutions (BLFS) closed down -$0.59 after Friday’s -$4.73, Thursday’s +$0.14, Wednesday’s +$3.29 and Tuesday’s +$1.06) with a negative -$0.23 or -0.43%

ReNeuron (RENE.L) closed flat twice (Monday & Friday) and has a pre-open down indication of -$5.25 or -2.09%

 

BUY:

Intellia Therapeutics (NTLA) closed up +$0.59 to $136.07 after Friday’s+$1.54 and Thursday’s -$1.97 with a negative +$0.93 or +0.68% pre-iron indication.

Fate Therapeutics (FATE) closed down -$0.63 to $60.79 after Friday’s +$1.77, Thursday’s -$0.73 and Wednesday’s +$2.52) with a positive +$1.42 or +2.34% aftermarket indication.

Editas Medicine (EDIT) closed up +$3.07 to $40.57 after Friday’s down again -$0.34 after Thursday’s -$0.85 with NLS (net -loss-per-share) earnings with an aftermarket of +$0.53 or +1.31%

 

 

The BOTTOM LINE: It's highly risky to buy a stock just before earnings, and investors may want to take whole or partial profits on holdings with tiny gains.

We are seeing to date, one (1) net income – Bellicum Pharmaceuticals (BLCM),

  • Eighteen (18) net losses to date <uniQure (QURE), Alnylam Pharmaceuticals (ALNY), Regenxbio (RGNX), Sage Therapeutics SAGE), Ultragenyx Pharmaceuticals (RARE), Voyager therapeutics (VYGR), Solid Biosciences (SLDB), Ionis Pharmaceuticals (IONS), CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA), Caladrius Biosciences (CLBS), AxoGen (AXGN), Adverum Biotechnologies (ADVM), Verastem (VSTM), Global Blood Therapeutics (GBT), Fate Therapeutics (FATE) and Sangamo Therapeutics (SGMO) and yesterday’s Editas Medicine (EDIT).

… Earning’s releases that initiated Q3 earnings reporting season and beginning the tug-of-war between share pricing that is softer than usual and the usual LPS (loss-per-share) to be less than estimates and expectations.

The stem, cell and gene therapy earnings with, Athersys (ATHX) and Brainstorm Cell Therapeutics (BCLI) coming 11/15 (to date).

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

WHY do I keep analyzing Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.